<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>COVID</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Montserrat:ital,wght@0,100..900;1,100..900&display=swap" rel="stylesheet">
</head>
<link rel="stylesheet" href="style.css">
<body>
        <li><h5 class="h5">CORRESPONDENCE</h5></li>
        <li> | </li>
        <li><h5>NOV 13, 2024</h5></li>
        <li> | </li>
        <li><h5 class="wew">FREE</h5></li>
    <img class="img" src="Torres.png" alt="chart">
    <p class="text"><b>
        Activity of Research-Grade
            Pemivibart against SARS-CoV-2
            Sublineages
    </b></p>
    <h4>Q. Wang and Others</h4>
    <p class="par">SARS-CoV-2 continues to evolve under immunologic pressure.
        A synthesized version of pemivibart, an anti-SARS-CoV-2 monoclonal
        antibody with recent emergency-use authorization, showed mixed activity 
        against emerging variants.
    </p>
    <p class="last"><b>Correction</b> Pemivibart Activity against Recent SARS-CoV-2 JN.1 Sublineages</p>
</body>
</html>